These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30729702)

  • 1. Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis.
    Kumthekar A; Shull S; Lovejoy TI; Morasco BJ; Chang M; Barton J
    Int J Rheum Dis; 2019 Apr; 22(4):592-598. PubMed ID: 30729702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection.
    Patel R; Mikuls TR; Richards JS; Kerr G; Cannon GW; Baker JF
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):467-74. PubMed ID: 25187185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pain, substance use disorders and opioid analgesic prescription patterns in veterans with hepatitis C.
    Whitehead AJ; Dobscha SK; Morasco BJ; Ruimy S; Bussell C; Hauser P
    J Pain Symptom Manage; 2008 Jul; 36(1):39-45. PubMed ID: 18358690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Prescription Opioid Therapy for Noncancer Pain and Hepatitis C Virus Seroconversion.
    Wilton J; Wong S; Purssell R; Abdia Y; Chong M; Karim ME; MacInnes A; Bartlett SR; Balshaw RF; Gomes T; Yu A; Alvarez M; Dart RC; Krajden M; Buxton JA; Janjua NZ
    JAMA Netw Open; 2022 Jan; 5(1):e2143050. PubMed ID: 35019983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of multidisciplinary chart reviews on opioid dose reduction and monitoring practices.
    Rivich J; McCauliff J; Schroeder A
    Addict Behav; 2018 Nov; 86():40-43. PubMed ID: 29752012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applicability of a new specialty pharmacy-reported measure describing completion of therapy for hepatitis C.
    Bolduc C; McCall K; Stickney K; Gelinas A; Levesque E
    J Manag Care Spec Pharm; 2021 Feb; 27(2):263-267. PubMed ID: 33506724
    [No Abstract]   [Full Text] [Related]  

  • 7. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.
    Lin M; Kramer J; White D; Cao Y; Tavakoli-Tabasi S; Madu S; Smith D; Asch SM; El-Serag HB; Kanwal F
    Aliment Pharmacol Ther; 2017 Nov; 46(10):992-1000. PubMed ID: 28949020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Improvements in Pain Intensity in a National Cohort of Older Veterans With Chronic Pain.
    Dobscha SK; Lovejoy TI; Morasco BJ; Kovas AE; Peters DM; Hart K; Williams JL; McFarland BH
    J Pain; 2016 Jul; 17(7):824-35. PubMed ID: 27058162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Chronic, Noncancer Pain Management Initiative in a Multidisciplinary Pain Clinic.
    Panicker L; Prasun MA; Stockmann C; Simon J
    Pain Manag Nurs; 2022 Apr; 23(2):122-127. PubMed ID: 34756689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An electronic intervention to improve safety for pain patients co-prescribed chronic opioids and benzodiazepines.
    Zaman T; Rife TL; Batki SL; Pennington DL
    Subst Abus; 2018; 39(4):441-448. PubMed ID: 29595408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Preoperative Opioid Use on Total Knee Arthroplasty Outcomes.
    Smith SR; Bido J; Collins JE; Yang H; Katz JN; Losina E
    J Bone Joint Surg Am; 2017 May; 99(10):803-808. PubMed ID: 28509820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using electronic health record's data to assess daily dose of opioids prescribed for outpatients with chronic non-cancer pain.
    Tuan WJ; Sehgal N; Zgierska AE
    Fam Med Community Health; 2021 Nov; 9(Suppl 1):. PubMed ID: 34819321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.
    Singal AG; Rich NE; Mehta N; Branch AD; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Ioannou GN; Huang A; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Kagan S; Gopal P; Wong R; Parikh ND; Murphy CC
    Gastroenterology; 2019 Nov; 157(5):1253-1263.e2. PubMed ID: 31374215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection.
    Rentsch CT; Cartwright EJ; Gandhi NR; Brown ST; Rodriguez-Barradas MC; Goetz MB; Marconi VC; Gibert CL; Re VL; Fiellin DA; Justice AC; Tate JP
    Ann Epidemiol; 2018 Nov; 28(11):808-811. PubMed ID: 30195616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort.
    Serper M; Forde KA; Kaplan DE
    J Viral Hepat; 2018 Feb; 25(2):187-197. PubMed ID: 28845882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
    Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
    Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
    Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
    Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of outcomes following high-dose opioid tapering in a Veterans Healthcare System.
    Hundley L; Spradley S; Donelenko S
    J Opioid Manag; 2018; 14(2):89-101. PubMed ID: 29733095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
    Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D
    Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.